Skip to main content
SpringerLink
Log in

New Therapies for Allergic Rhinitis

  • RHINITIS (JJ OPPENHEIMER AND J CORREN, SECTION EDITORS)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Because of its burden on patient’s lives and its impact on asthma, allergic rhinitis must be treated properly with more effective and safer treatments. According to guidelines by Allergic Rhinitis and Its Impact on Asthma (ARIA), the classification, pathogenesis, and treatment of allergic rhinitis are well defined. Currently, second-generation antihistamines and inhaled steroids are considered the cornerstone of first-line therapy. However, new formulations of available drugs (e.g., loratadine and rupatadine oral solution, ebastine fast-dissolving tablets, and the combination of intranasal fluticasone propionate and azelastine hydrochloride), recently discovered molecules (e.g., ciclesonide, bilastine, and phosphodiesterase-4 inhibitors), immunologic targets (e.g., omalizumab), and unconventional treatments (e.g., homeopathic treatments) are currently under investigation and represent a new frontier in modern medicine and in allergic rhinitis management. The aim of this review is to provide an update on allergic rhinitis treatment, paying particular attention to clinical trials published within the past 20 months that assessed the efficacy and safety of new formulations of available drugs or new molecules.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8–160.

    Article  PubMed  Google Scholar 

  2. Burbach GJ, Heinzerling LM, Edenharter G, et al. GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy. 2009;64:1507–15.

    Article  PubMed  CAS  Google Scholar 

  3. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008;38:19–42.

    Article  PubMed  CAS  Google Scholar 

  4. Juniper E, Stahl E, Doty R, et al. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol. 2005;115:S390–413.

    Article  PubMed  Google Scholar 

  5. Montoro J, Del Cuvillo A, et al. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study. Allergy. 2012;67:1437–42.

    Article  PubMed  CAS  Google Scholar 

  6. Brozek JL, Bousquet J, Baena-Cagnani CE, Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466–76. This article provides a clear and detailed example of the application of the GRADE approach to compiling evidence and evaluating the quality of evidence, and also provides a grading of recommendation in updating ARIA guidelines.

    Article  PubMed  Google Scholar 

  7. Price D. Asthma and allergic rhinitis: linked in treatment and outcomes. Ann Thorac Med. 2010;5:63–4.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Compalati E, Ridolo E, Passalacqua G, et al. The link between allergic rhinitis and asthma: the united airways disease. Expert Rev Clin Immunol. 2010;6:413–23.

    Article  PubMed  Google Scholar 

  9. Knight LC, Eccles R, Morris S. Seasonal allergic rhinitis and its effects on eustachian tube function and middle ear pressure. Clin Otolaryngol Allied Sci. 1992;17:308–12.

    Article  PubMed  CAS  Google Scholar 

  10. Pinto JM, Baroody FM. Chronic sinusitis and allergic rhinitis: at the nexus of sinonasal inflammatory disease. J Otolaryngol. 2002;31:S10–7.

    Article  PubMed  Google Scholar 

  11. Slavin RG. Complications of allergic rhinitis: implications for sinusitis and asthma. J Allergy Clin Immunol. 1998;101:S357–60.

    Article  PubMed  CAS  Google Scholar 

  12. Craig TJ, Sherkat A, Safaee S. Congestion and sleep impairment in allergic rhinitis. Curr Allergy Asthma Rep. 2010;10:113–21.

    Article  PubMed  Google Scholar 

  13. Muliol J, Maurer M, Bousquet J. Sleep and allergic rhinitis. J Investig Allergol Clin Immunol. 2008;18:415–9.

    PubMed  CAS  Google Scholar 

  14. Storms W, Yawn B, Fromer L. Therapeutic options for reducing sleep impairment in allergic rhinitis, rhinosinusitis, and nasal polyposis. Curr Med Res Opin. 2007;23:2135–46.

    Article  PubMed  Google Scholar 

  15. Bachert C, Vignola AM, Gevaert P, et al. Allergic rhinitis, rhinosinusitis, and asthma: one airway disease. Immunol Allergy Clin North Am. 2004;24:19–43.

    Article  PubMed  Google Scholar 

  16. Jeffery PK, Haahtela T. Allergic rhinitis and asthma: inflammation in a one airway condition. BMC Pulm Med. 2006;6 Suppl 1:S5.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Cruz AA, Popov T, Pawankar R, ARIA Initiative Scientific Committee, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy. 2007;62:1–41.

    Article  PubMed  Google Scholar 

  18. Passalacqua G, Ciprandi G, Canonica GW. The nose–lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol. 2001;1:7–13.

    PubMed  CAS  Google Scholar 

  19. Leynaert B, Bousquet J, Neukirch C, et al. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol. 1999;104:301–4.

    Article  PubMed  CAS  Google Scholar 

  20. Rochat MK, Illi S, Ege MJ, Multicentre Allergy Study (MAS) group. Allergic rhinitis as a predictor for wheezing onset in school-aged children. J Allergy Clin Immunol. 2010;126:1170–5.

    Article  PubMed  Google Scholar 

  21. Smart BA. Is rhinosinusitis a cause of asthma? Clin Rev Allergy Immunol. 2006;30:153–64.

    Article  PubMed  Google Scholar 

  22. Wu KG, Li TH, Wang TY, et al. A comparative study of loratadine syrup and cyproheptadine HCL solution for treating perennial allergic rhinitis in Taiwanese children aged 2-12 years. Int J Immunopathol Pharmacol. 2012;25:231–7.

    PubMed  CAS  Google Scholar 

  23. Fantin S, Maspero J, Bisbal C, International Rupatadine Study Group, et al. A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy. 2008;63:924–31.

    Article  PubMed  CAS  Google Scholar 

  24. Guadano EM, Serra-Batlles J, Meseguer J, Rupatadine Study Group, et al. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy. 2004;59:766–71.

    Article  PubMed  CAS  Google Scholar 

  25. Potter P, Maspero JF, Vermeulen J, et al. Rupatadine oral solution in children with persistent allergic rhinitis: a randomized, double-blind, placebo-controlled study. Pediatr Allergy Immunol. 2013;24:144–50.

    Article  PubMed  Google Scholar 

  26. Juniper EF, Howland WC, Roberts NB, et al. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol. 1998;101:163–70.

    Article  PubMed  CAS  Google Scholar 

  27. Salvà M, Carreno B, Pintos M, et al. Phase I, single dose, open-label, randomized, cross-over bio-equivalence studies of ebastine 10 mg and 20 mg fast-dissolving tablets in healthy male volunteers. J Investig Allergol Clin Immunol. 2004;14:S5.

    Google Scholar 

  28. Ciprandi G. Clinical utility and patient adherence in the use of ebastine for allergic rhinitis. Patient Prefer Adherence. 2010;4:389–95.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Luskin AT, Blaiss MS, Farrar JR, et al. Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis. Allergy Asthma Proc. 2011;32:168–77.

    Article  PubMed  CAS  Google Scholar 

  30. Meltzer EO, Jacobs RL, LaForce CF, et al. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc. 2012;33:249–57.

    PubMed  CAS  Google Scholar 

  31. Ratner PH, Melchior A, Dunbar SA, et al. Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study. Clin Ther. 2012;34:1422–31.

    Article  PubMed  CAS  Google Scholar 

  32. Passalacqua G, Ciprandi G. Novel therapeutic interventions for allergic rhinitis. Expert Opin Investig Drugs. 2006;15:1615–25.

    Article  PubMed  CAS  Google Scholar 

  33. Chervinsky P, Kunjibettu S, Miller DL, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2007;99:69–76.

    Article  PubMed  CAS  Google Scholar 

  34. Ratner PH, Andrews C, Martin B, et al. A study of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol in patients with seasonal allergic rhinitis from mountain cedar pollen. Allergy Asthma Proc. 2012;33:27–35.

    Article  PubMed  CAS  Google Scholar 

  35. Varshney J, Varshney H, Dutta SK, et al. Comparison of sensory attributes and immediate efficacy of intranasal ciclesonide and fluticasone propionate in allergic rhinitis: a randomized controlled trial. Indian J Pharmacol. 2012;44:550–4.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  36. Meltzer EO, LaForce C, Ratner P, et al. MP29-02 A novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012;33:324–32.

    Article  PubMed  CAS  Google Scholar 

  37. Barnes PJ. Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol. 1999;104:S10–7.

    Article  PubMed  CAS  Google Scholar 

  38. Russo C, Zeng D, Prosperini G, et al. Effect of salbutamol on nasal symptoms and mast cell degranulation induced by adenosine 5’ monophosphate nasal challenge. Clin Exp Allergy. 2005;35:1192–6.

    Article  PubMed  CAS  Google Scholar 

  39. Lipworth BJ, Short P, Burns P, Nair A. Effects of intranasal salmeterol and fluticasone given alone and in combination in persistent allergic rhinitis. Ann Allergy Asthma Immunol. 2012;108:54–9.

    Article  PubMed  CAS  Google Scholar 

  40. Ahlström-Emanuelsson C, Andersson M, Persson C, et al. Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis. Clin Exp Allergy. 2004;34:731–5.

    Article  PubMed  Google Scholar 

  41. Erin EM, Leaker BR, Zacharasiewicz A, et al. Effects of a reversible beta-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses. Clin Exp Allergy. 2006;36:458–64.

    Article  PubMed  CAS  Google Scholar 

  42. Rimmer J, Peake HL, Santos CM. Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2007;37:8–14.

    Article  PubMed  CAS  Google Scholar 

  43. Schmidt BM, Kusma M, Feuring M, et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol. 2001;108:530–6.

    Article  PubMed  CAS  Google Scholar 

  44. Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001;193:255–61.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  45. Pettipher R. The roles of the prostaglandin D2 receptors DP1 and CRTH2 in promoting allergic responses. Br J Pharmacol. 2008;153:S191–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  46. Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy. 2012;42:38–48.

    Article  PubMed  CAS  Google Scholar 

  47. Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012;67:1572–9.

    PubMed  CAS  Google Scholar 

  48. Horak F, Stubner P, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol. 2001;125:73–9.

    Article  PubMed  CAS  Google Scholar 

  49. Zieglmayer P, Zieglmayer R, Bareille P, et al. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin. 2008;24:1833–40.

    Article  PubMed  CAS  Google Scholar 

  50. Corcóstegui R, Labeaga L, Innerárity A, et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D. 2005;6:371–84.

    Article  PubMed  Google Scholar 

  51. Bachert C, Kuna P, Sanquer F, Bilastine International Working Group, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009;64:158–65.

    Article  PubMed  CAS  Google Scholar 

  52. Corcóstegui R, Labeaga L, Innerárity A, et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D. 2006;7:219–31.

    Article  PubMed  Google Scholar 

  53. Church MK. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans. Inflamm Res. 2011;60(12):1107–12.

    Article  PubMed  CAS  Google Scholar 

  54. Horak F, Zieglmayer P, Zieglmayer R, et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010;59:391–8.

    Article  PubMed  CAS  Google Scholar 

  55. Kuna P, Bachert C, Nowacki Z, Bilastine International Working Group, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009;39:1338–47.

    Article  PubMed  CAS  Google Scholar 

  56. Jauregizar N, Fuente LDL, Lucero ML, et al. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet. 2009;48:543–54.

    Article  PubMed  CAS  Google Scholar 

  57. Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci. 2012;16:1999–2005.

    PubMed  CAS  Google Scholar 

  58. Tyl B, Kabbaj M, Azzam S, et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol. 2012;52:893–903.

    Article  PubMed  CAS  Google Scholar 

  59. Lazewska D, Kiec-Kononowicz K. Azines as histamine H4 receptor antagonists. Front Biosci (Schol Ed). 2012;4:967–87.

    Article  Google Scholar 

  60. Kiss R, Keserű GM. Histamine H4 receptor ligands and their potential therapeutic applications: an update. Expert Opin Ther Pat. 2012;22:205–21.

    Article  PubMed  CAS  Google Scholar 

  61. Daley-Yates P, Ambery C, Sweeney L, et al. The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol. 2012;158:84–98.

    Article  PubMed  CAS  Google Scholar 

  62. Furukido K, Takeno S, Ueda T, et al. Suppression of the Th2 pathway by suplatast tosilate in patients with perennial nasal allergies. Am J Rhinol. 2002;16:329–36.

    PubMed  Google Scholar 

  63. Tan Y, Li Y, Liu D, et al. Suplatast tosilate ameliorates airway hyperreactivity and inflammation through inhibition of the GATA‑3/IL‑5 signaling pathway in asthmatic rats. Mol Med Rep. 2013;8:161–7.

    PubMed  CAS  Google Scholar 

  64. Casale TB. Experience with monoclonal antibodies in allergic mediated disease: seasonal allergic rhinitis. J Allergy Clin Immunol. 2001;108:S84–8.

    Article  PubMed  CAS  Google Scholar 

  65. Grundmann SA, Hemfort PB, Luger TA, et al. Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol. 2008;121:257–8.

    Article  PubMed  CAS  Google Scholar 

  66. Casale TB, Stokes JR. Future forms of immunotherapy. J Allergy Clin Immunol. 2011;127:8–15.

    Article  PubMed  Google Scholar 

  67. Senti G, Prinz Vavricka BM. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105:17908–12.

    Article  PubMed Central  PubMed  Google Scholar 

  68. Senti G, von Moos S, Kündig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy. 2011;66:798–809.

    Article  PubMed  CAS  Google Scholar 

  69. Holgate ST. The epidemic of asthma and allergy. J R Soc Med. 2004;97:103–10.

    Article  PubMed Central  PubMed  Google Scholar 

  70. Creticos PS, Eiden JJ, Broide DH, et al. Immunotherapy with immunostimulatory oligonucleotides linked to purified ragweed Amb a1 allergen: effects on antibody production, nasal allergen provocation, and ragweed seasonal rhinitis. J Allergy Clin Immunol. 2002;109:743–4.

    Article  Google Scholar 

  71. Drachenber KJ, Wheeler A, Stubner P, et al. A well tolerated grass pollen specific allergy vaccine containing a novel adjuvant MPL reduces allergy symptoms after only four preseasonal injections. Allergy. 2001;56:498–505.

    Article  Google Scholar 

  72. Greiff L, Cervin A, Ahlström-Emanuelsson C, et al. Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012;13:53.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  73. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122:951–60.

    Article  PubMed  CAS  Google Scholar 

  74. Bareille P, Murdoch RD, Denyer J, et al. The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. Int J Clin Pharmacol Ther. 2013;51:576–84.

    Article  PubMed  CAS  Google Scholar 

  75. Saito H, Morikawa H, Howie K. Effects of a cysteinyl leukotriene receptor antagonist on eosinophil recruitment in experimental allergic rhinitis. Immunology. 2004;113:246–52.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  76. Lue KH, Sun HL, Lu KH, et al. A trial of adding Lactobacillus johnsonii EM1 to levocetirizine for treatment of perennial allergic rhinitis in children aged 7-12 years. Int J Pediatr Otorhinolaryngol. 2012;76:994–1001.

    Article  PubMed  Google Scholar 

  77. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259–60.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  78. Wheeler JG, Bogle ML, Shema SJ, et al. Impact of dietary yogurt on immune function. Am J Med Sci. 1997;313:120–3.

    Article  PubMed  CAS  Google Scholar 

  79. Pessi T, Sütas Y, Hurme M, et al. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy. 2000;30:1804–8.

    Article  PubMed  CAS  Google Scholar 

  80. Smits HH, Engering A, van der Kleij D, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol. 2005;115:1260–7.

    Article  PubMed  CAS  Google Scholar 

  81. Di Giacinto C, Marinaro M, Sanchez M, et al. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol. 2005;174:3237–46.

    Article  PubMed  Google Scholar 

  82. Lammers KM, Brigidi P, Vitali B, et al. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol. 2003;38:165–72.

    Article  PubMed  CAS  Google Scholar 

  83. Singh A, Hacini-Rachinel F, Gosoniu ML, et al. Immune-modulatory effect of probiotic Bifidobacterium lactis NCC2818 in individuals suffering from seasonal allergic rhinitis to grass pollen: an exploratory, randomized, placebo-controlled clinical trial. Eur J Clin Nutr. 2013;67:161–7.

    Article  PubMed  CAS  Google Scholar 

  84. Böhm M, Avgitidou G, El Hassan E, et al. Liposomes: a new non-pharmacological therapy concept for seasonal-allergic-rhinoconjunctivitis. Eur Arch Otorhinolaryngol. 2012;269:495–502.

    Article  PubMed Central  PubMed  Google Scholar 

  85. Sayed R, Abou-Elhamd K, Abdel-Kader M, et al. Study of surfactant level in cases of primary atrophic rhinitis. J Laryngol Otol. 2000;114:254–9.

    Article  PubMed  CAS  Google Scholar 

  86. Yarosh D. Topical application of liposomes. J Photochem Photobiol B. 1990;6:445–9.

    Article  PubMed  CAS  Google Scholar 

  87. D’Amato G, Liccardi G, Salzillo A, et al. Nasal filters in prevention of seasonal rhinitis induced by allergenic pollen grains. Open clinical study. Eur Ann Allergy Clin Immunol. 2012;44:83–5.

    PubMed  Google Scholar 

  88. Marchisio P, Varricchio A, Baggi E, et al. Hypertonic saline is more effective than normal saline in seasonal allergic rhinitis in children. Int J Immunopathol Pharmacol. 2012;25:721–30.

    PubMed  CAS  Google Scholar 

  89. Rabago D, Zgierska A. Saline nasal irrigation for upper respiratory conditions. Am Fam Physician. 2009;80:1117–9.

    PubMed  Google Scholar 

  90. Parsons DS. Chronic sinusitis: a medical or surgical disease? Otolaryngol Clin North Am. 1996;29:1–9.

    PubMed  CAS  Google Scholar 

  91. Gupta R, Sheikh A, Strachan DP, et al. Increasing hospital admissions for systemic allergic disorders in England: analysis of national admissions data. BMJ. 2003;327:1142–3.

    Article  PubMed Central  PubMed  Google Scholar 

  92. Strannegard O, Strannegard IL. The causes of the increasing prevalence of allergy: is atopy a microbial deprivation disorder? Allergy. 2001;56:91–102.

    Article  PubMed  CAS  Google Scholar 

  93. Gründling C, Schimetta W, Frass M. Real-life effect of classical homeopathy in the treatment of allergies: a multicenter prospective observational study. Wien Klin Wochenschr. 2012;124:11–7.

    Article  PubMed  Google Scholar 

  94. Choi SM, Park JE, Li SS, et al. A multicenter, randomized, controlled trial testing the effects of acupuncture on allergic rhinitis. Allergy. 2013;68:365–74.

    Article  PubMed  CAS  Google Scholar 

  95. Reinhold T, Roll S, Willich SN, et al. Cost-effectiveness for acupuncture in seasonal allergic rhinitis: economic results of the ACUSAR trial. Ann Allergy Asthma Immunol. 2013;111:56–63.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The study was supported by ARMIA (Associazione Ricerca Malattie Immunologiche e Allergiche).

The authors thank ASPADIRES (Associazione Pazienti Disturbi Respiratori nel Sonno) and acknowledge Dr. Marianna Bruzzone for linguistic assistance with the manuscript.

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Fulvio Braido, F. Sclifò, M. Ferrando, and G.W. Canonica declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Allergy & Respiratory Diseases Clinic – DIMI, University of Genoa, IRCCS AOU San Martino-IST, Pad. Maragliano, Largo Rosanna Benzi 10, 16132, Genova, Italy

    Fulvio Braido, Francesca Sclifò, Matteo Ferrando & Giorgio Walter Canonica

Authors
  1. Fulvio Braido
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Sclifò
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matteo Ferrando
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giorgio Walter Canonica
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fulvio Braido.

Additional information

F. Sclifò and M. Ferrando contributed equally to the paper

This article is part of the Topical Collection on Rhinitis

Rights and permissions

Reprints and permissions

About this article

Cite this article

Braido, F., Sclifò, F., Ferrando, M. et al. New Therapies for Allergic Rhinitis. Curr Allergy Asthma Rep 14, 422 (2014). https://doi.org/10.1007/s11882-014-0422-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11882-014-0422-z

Keywords

Search

Navigation